Compare Albemarle Corp. (ALB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Neurocrine Biosciences Inc — how do they compare? Albemarle Corp. trades at $128.74 (market cap $15.27B), while Neurocrine Biosciences Inc trades at $158.94 (market cap $16.46B). The key difference: Albemarle Corp. and Neurocrine Biosciences Inc are close in size by market cap, and Albemarle Corp. pays a 1.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ALB | NBIX | |
|---|---|---|
Market Cap | $15.27B | $16.46B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $185.50 |
52-Week Low | $72.58 | $123.10 |
Enterprise Value | $17.75B | $16.48B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $131.21, up 0.08% on the day, showing a bullish technical trend with strong support at $129 and resistance at $133. The company reported robust Q2 2026 results, beating EPS estimates with $3.75 versus $3.20 expected, driven by improved lithium pricing and specialties growth. However, net income remains negative for 2025 at -$510.63M, and the P/E ratio is elevated at 479.11, indicating high valuation expectations. Analyst sentiment is mixed with a consensus price target of $184.50 but only 42% buy ratings.
Outlook: ALB benefits from strong lithium demand and cost controls, but faces risks from volatile lithium prices and sequential margin pressure in Q3. The stock offers growth potential if execution continues, yet high valuation and earnings inconsistency warrant caution. Near-term price action hinges on Q3 results and lithium market trends.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
